Zealand Pharma A/S

Zealand Pharma A/S is a Danish biotechnology company dedicated to the discovery, design, and development of peptide-based medicines, primarily focusing on obesity and metabolic health. Headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts, and New York City, USA, the company aims to become a generational biotech leader in its field.

Zealand Pharma's therapeutic focus areas include obesity, rare diseases such as congenital hyperinsulinism and short bowel syndrome, and chronic inflammation. The company boasts a robust pipeline of novel candidates, with over ten drug candidates having advanced into clinical development, and two products already on the market. Key pipeline assets include petrelintide, survodutide, dasiglucagon, glepaglutide, and ZP9830. Zealand Pharma frequently engages in strategic partnerships for co-development and commercialization to extend its capabilities.

Under the leadership of CEO Dr. Adam Steensberg, Zealand Pharma unveiled its "Metabolic Frontier 2030" strategy in December 2025, targeting five product launches and more than ten clinical pipeline programs by 2030, leveraging its peptide expertise and AI-driven drug discovery. Recent notable advancements include progressing petrelintide to Phase 3 trials in collaboration with Roche and positive Phase 3 results for survodutide, developed with Boehringer Ingelheim, demonstrating significant weight loss in obesity trials. The company reported substantial revenue growth in Q3 2025, largely driven by upfront payments from its strategic partnerships.